Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director · 10% owner | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectRichard E. Uihlein Stock Trust | 42,162,911 |
Reported balance
After 2026-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-31 · Exercise / conversion · Acquired 31,825,235 · Balance 42,162,911 |
| Common StockSEC Table I · non-derivative | IndirectRichard E. Uihlein Stock Trust | 44,713,843 |
Reported balance
After 2026-07-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-31 · Exercise / conversion · Acquired 2,550,932 · Balance 44,713,843 |
| Line of Credit Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2027-06-30 | IndirectRichard E. Uihlein Stock Trust | 0 |
Reported balance
After 2026-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-31 · Exercise / conversion · Disposed Not disclosed · Balance 0 F1: Consists of $91,000,000 in principal and $14,475,705 in accrued interest. F3: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. |
| Line of Credit Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2027-06-30 | IndirectRichard E. Uihlein Stock Trust | 0 |
Reported balance
After 2026-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-31 · Exercise / conversion · Disposed Not disclosed · Balance 0 F2: Consists of $10,000,000 of principal and $331,275 of accrued interest. F3: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy Ed Uihlein Family Foundation | 27,710 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,710 F4: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of $91,000,000 in principal and $14,475,705 in accrued interest.
F2: Consists of $10,000,000 of principal and $331,275 of accrued interest.
F3: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027.
F4: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionLine of Credit Convertible Notes · Derivative | Not disclosed | $10,331,275.00 Strike: $4.05 | $10,331,275.00 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · derivative · entry 5 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 0 Underlying: Common Stock · 2,550,932 shares Expires 2027-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · reported_value: Consists of $10,000,000 of principal and $331,275 of accrued interest. F2 · price: Consists of $10,000,000 of principal and $331,275 of accrued interest. F3 · derivative.exercise_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. F3 · derivative.expiration_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionLine of Credit Convertible Notes · Derivative | Not disclosed | $95,475,705.00 Strike: $3.00 | $95,475,705.00 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · derivative · entry 4 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 0 Underlying: Common Stock · 31,825,235 shares Expires 2027-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · reported_value: Consists of $91,000,000 in principal and $14,475,705 in accrued interest. F1 · price: Consists of $91,000,000 in principal and $14,475,705 in accrued interest. F3 · derivative.exercise_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. F3 · derivative.expiration_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 2,550,932 | $4.05 | $10,331,274.60 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 44,713,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 31,825,235 | $3.00 | $95,475,705.00 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 42,162,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:44 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000020 · form4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:44 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 13,158 | $3.04 | $40,000.32 |
DisclosureSEC source: 0001133416-26-000020 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,332,676 F3 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026. F3 · price: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:09 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000022 · form4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-01-23 F3 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_date: The options vest 100% on December 31, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:09 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 32,520 | $1.23 | $39,999.60 |
DisclosureSEC source: 0001133416-25-000022 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,301,271 F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024. Read SEC document |
| January 24, 2024 Filed Feb 7, 2024 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-24-000026 · form4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-24 F3 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_date: The options vest 100% on December 31, 2024. Read SEC document |
| January 24, 2024 Filed Feb 7, 2024 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 23,256 | $1.72 | $40,000.32 |
DisclosureSEC source: 0001133416-24-000026 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,268,751 F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · derivative · entry 11 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · derivative · entry 10 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · derivative · entry 9 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 170,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · derivative · entry 8 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 170,000 shares Expires 2029-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 1,466,204 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · derivative · entry 7 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,466,204 shares Expires 2023-12-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 200,000 | $3.00 | $600,000.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · nonDerivative · entry 5 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,235,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 200,000 | $3.26 | $652,000.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · nonDerivative · entry 4 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,035,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 200,000 | $3.00 | $600,000.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · nonDerivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,835,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 170,000 | $5.00 | $850,000.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,635,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 18:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 1,466,204 | $5.00 | $7,331,020.00 |
DisclosureSEC source: 0001133416-23-000075 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,466,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-23-000008 · form4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-01-26 F3 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_date: The options vest 100% on December 31, 2023. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 36,036 | $1.11 | $39,999.96 |
DisclosureSEC source: 0001133416-23-000008 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,999,291 F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2023. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2023. Read SEC document |
| January 24, 2022 Filed Feb 8, 2022 14:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-22-000043 · form4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-24 F3 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_date: The options vest 100% on December 31, 2022. Read SEC document |
| January 24, 2022 Filed Feb 8, 2022 14:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 17,677 | $1.98 | $35,000.46 |
DisclosureSEC source: 0001133416-22-000043 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,936,677 F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022. Read SEC document |
| December 20, 2021 Filed Jan 25, 2022 21:29 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantConvertible Note · Derivative | 1,841,621 | $10,000,000.00 Strike: $5.43 | $18,416,210,000,000.00 |
DisclosureSEC source: 0001133416-22-000026 · form4.xml · derivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 Underlying: Common Stock · 1,841,621 shares Expires 2025-12-20 F1 · shares: Excludes interest that may accrue following issuance of the Note. F3 · price: In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company. F2 · derivative.exercise_date: The Note is convertible upon 60 days prior written notice by the Noteholder. F4 · balance_after: Represents the principal amount of the Convertible Note payable. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 20:30 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantConvertible Note · Derivative | 1,157,407 | $10,000,000.00 Strike: $8.64 | $11,574,070,000,000.00 |
DisclosureSEC source: 0000899243-21-036780 · doc4.xml · derivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 Underlying: Common Stock · 1,157,407 shares Expires 2025-09-17 F1 · shares: Excludes interest that may accrue following issuance of the Note. F3 · price: In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company. F2 · derivative.exercise_date: The Note is convertible upon 60 days prior written notice by the noteholder. F1 · derivative.underlying_shares: Excludes interest that may accrue following issuance of the Note. F4 · balance_after: Represents the principal amount of the note payable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 21:00 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantConvertible Note · Derivative | 2,000,000 | $10,000,000.00 Strike: $5.00 | $20,000,000,000,000.00 |
DisclosureSEC source: 0000899243-21-016234 · doc4.xml · derivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2025-04-16 F1 · shares: Excludes interest that may accrue following issuance of the Note. F3 · price: In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company. F2 · derivative.exercise_date: The Note is convertible upon 60 days prior written notice by the noteholder. F1 · derivative.underlying_shares: Excludes interest that may accrue following issuance of the Note. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013817 · doc4.xml · derivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013817 · doc4.xml · derivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such options vest 100% on March 31, 2022. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 12:00 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 10,000 | $2.55 | $25,500.00 |
DisclosureSEC source: 0000899243-20-024606 · doc4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893,191 Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 18,638 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0000899243-20-004591 · doc4.xml · derivative · entry 5 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,362 Underlying: Common Stock · 18,638 shares Expires 2029-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The options were issued pursuant to Galectin Therapeutics' Amended and Restated 2009 Incentive Stock Plan. F4 · derivative.exercise_date: The options became fully vested on January 16, 2020. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 46,875 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0000899243-20-004591 · doc4.xml · derivative · entry 4 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,875 shares Expires 2027-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The options were issued pursuant to Galectin Therapeutics' Amended and Restated 2009 Incentive Stock Plan. F3 · derivative.exercise_date: The options became fully vested on December 14, 2018. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 18,638 | $4.72 | $87,971.36 |
DisclosureSEC source: 0000899243-20-004591 · doc4.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,883,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 46,875 | $2.39 | $112,031.25 |
DisclosureSEC source: 0000899243-20-004591 · doc4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,864,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:09 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001131 · doc4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-01-09 F3 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_date: The options vest 100% on December 31, 2020. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:09 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 12,238 | $2.86 | $35,000.68 |
DisclosureSEC source: 0000899243-20-001131 · doc4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,817,678 F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2020. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2020. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 25,700 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000038 · edgar.xml · derivative · entry 6 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ed Uihlein Family Foundation Disclosed balance after: 25,700 Underlying: Common Stock · 1,927 shares Expires 2026-05-31 F2 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F3 · derivative.exercise_date: This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II. There are no amendments to Table I. F3 · derivative.expiration_date: This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II. There are no amendments to Table I. F2 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F1 · ownership.nature: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 15,576,322 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000038 · edgar.xml · derivative · entry 5 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,576,322 Underlying: Common Stock · 1,168,253 shares Expires 2026-05-31 F3 · date: This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II. There are no amendments to Table I. F2 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F2 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 7,710 | $4.28 | $32,998.80 |
DisclosureSEC source: 0001179022-19-000038 · edgar.xml · nonDerivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ed Uihlein Family Foundation Disclosed balance after: 27,710 F1 · ownership.nature: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 4,672,896 | $4.28 | $19,999,994.88 |
DisclosureSEC source: 0001179022-19-000038 · edgar.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,801,385 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 25,700 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000032 · edgar.xml · derivative · entry 6 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ed Uihlein Family Foundation Disclosed balance after: 25,700 Underlying: Common Stock · 1,927 shares Expires 2026-06-03 F2 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F2 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F1 · ownership.nature: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 7,710 | $4.28 | $32,998.80 |
DisclosureSEC source: 0001179022-19-000032 · edgar.xml · nonDerivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ed Uihlein Family Foundation Disclosed balance after: 27,710 F1 · ownership.nature: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 4,672,896 | $4.28 | $19,999,994.88 |
DisclosureSEC source: 0001179022-19-000032 · edgar.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,801,385 Read SEC document |
| May 29, 2019 Filed Jun 3, 2019 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 500,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000038 · edgar.xml · derivative · entry 4 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,204 Underlying: Common Stock · 500,000 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II. There are no amendments to Table I. Read SEC document |
| May 29, 2019 Filed Jun 3, 2019 22:10 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 500,000 | $5.00 | $2,500,000.00 |
DisclosureSEC source: 0001179022-19-000038 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,128,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed Jun 3, 2019 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 15,576,322 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000032 · edgar.xml · derivative · entry 5 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,576,322 Underlying: Common Stock · 1,168,253 shares Expires 2026-05-31 F2 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F2 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. Read SEC document |
| May 29, 2019 Filed Jun 3, 2019 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 500,000 | $5.00 | $2,500,000.00 |
DisclosureSEC source: 0001179022-19-000032 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,128,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2019 Filed Jun 3, 2019 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock Purchase Warrant (right to buy) · Derivative | 500,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000032 · edgar.xml · derivative · entry 4 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,204 Underlying: Common Stock · 500,000 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 20:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 20,700 | $4.82 | $99,850.59 |
DisclosureSEC source: 0001179022-19-000031 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,628,489 F1 · price: The shares were purchased in multiple transactions at prices ranging from $4.80 to $4.85. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 21,000 | $4.81 | $100,972.20 |
DisclosureSEC source: 0001179022-19-000029 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,607,789 F1 · price: The shares were purchased in multiple transactions at prices ranging from $4.789 to $4.810. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.